Fusion antigen of Haemophilus parasuis and its application
A recombinant fusion antigen of HAPS0629, LppC, and VacJ proteins addresses the limitations of current Haemophilus parasuis vaccines by offering broad-spectrum protection and enhanced immune responses against multiple serotypes, outperforming traditional vaccines in efficacy.
Patent Information
- Application Number
- CN202410627552.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-05-21
AI Technical Summary
Current vaccines for Haemophilus parasuis provide limited serotype antigen coverage, lacking broad-spectrum protection and effective cross-immunity, making them inadequate for preventing the diverse serotypes prevalent in pig farms.
A fusion antigen comprising the HAPS0629, LppC, and VacJ proteins, which are surface antigens with rich epitopes, is constructed through splicing their gene sequences to create a recombinant vaccine that offers cross-protection against multiple serotypes.
The fusion antigen induces robust immune responses, providing better protection against highly pathogenic Haemophilus parasuis serotypes than traditional vaccines, with improved immunoreactivity and reduced immune stress.
Smart Images

Figure CN118388664B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pathogenic bacteria disease prevention and treatment, and specifically relates to a Glaesserella parasuis fusion antigen and application thereof. Background Art
[0002] With the highly intensive development of pig farming, the increasing density of breeding per unit volume and the strict reduction of veterinary antibiotics in clinical production have provided favorable opportunities for the breeding and spread of pig bacterial diseases. After African swine fever, blue ear disease, pseudorabies and other important pig viral diseases have achieved good prevention and control and purification effects by relying on strict biosafety measures, the trend of pig bacterial diseases rising and spreading in pig herds has become more obvious. Among them, Glaesserella parasuis (GPS) is more common and prevalent in current large-scale pig farms. It is one of the important bacterial diseases that cause morbidity and mortality of piglets in the nursery stage in intensive pig farms, which seriously restricts the stable and healthy development of pig farming. The pathogen often lurks in the upper respiratory tract of pigs and does not cause corresponding clinical symptoms; when pigs are affected by the internal and external environment such as large changes in temperature and humidity in the house or poor ventilation, it is easy to induce clinical symptoms such as fibrinous polyserositis, pleurisy, arthritis and meningitis caused by the pathogen. When clinical symptoms caused by Haemophilus parasuis are found in the pig herd, the best prevention and control effect has often been missed by using drugs to prevent and control the pig herd. Therefore, the most economical and effective prevention and control method is to use safe, efficient and broad-spectrum vaccines for early immunization.
[0003] However, the current vaccine serotype antigen spectrum for the prevention and control of Haemophilus parasuis disease is relatively narrow, mostly serotype 4 strain antigens and serotype 5 strain antigens. Using traditional serotype identification methods, more than 15 serotypes of Haemophilus parasuis prevalent in clinical practice have been identified, of which serotypes 1, 5, 10, 12, 13 and 14 are highly pathogenic serotypes; serotypes 2, 4, 8 and 15 are moderately pathogenic serotypes; serotypes 3, 6, 7, 9 and 11 are non-pathogenic serotypes, and there is a lack of safe and effective cross-immunity protection between the serotypes, and the prevalent serotypes of Haemophilus parasuis in the same pig farm are constantly changing. Therefore, the existing vaccines with limited serotype antigens for Haemophilus parasuis disease are difficult to provide good cross-protection.
[0004] Therefore, it is of great significance to develop a vaccine that can simultaneously protect against multiple serotypes of Haemophilus parasuis. Summary of the invention
[0005] Based on the above problems, the present invention has discovered the common immune protective antigens HAPS0629 protein, LppC protein and VacJ protein that are potential in different serotypes of Haemophilus parasuis in the early screening of a large number of immune protective antigens of Haemophilus parasuis. Through relevant biological information analysis, the three screened immune protective proteins are all located on the surface of Haemophilus parasuis bacteria, and the entire amino acid sequence of HAPS0629 protein antigen and VacJ protein antigen contains rich B cell antigen epitopes, cytotoxic T cell antigen epitopes and helper T cell antigen epitopes. The immune cell antigen epitope of LppC protein antigen is mainly located in the middle region of the amino acid sequence. Therefore, the gene sequence of the middle region of LppC protein antigen is selected, and its two ends are seamlessly spliced with HAPS0629 protein gene and VacJ protein gene respectively, to construct a spliced sequence expression vector, and induce expression to obtain a fusion protein antigen of HAPS0629 protein antigen + LppC protein middle region antigen + VacJ protein antigen, which can achieve cross-immune protection against highly pathogenic serotypes of Haemophilus parasuis.
[0006] In order to achieve the above object, the present invention can adopt the following technical solutions:
[0007] On one hand, the present invention provides a Glaesserella parasuis fusion antigen, whose amino acid sequence is shown in SEQ ID NO: 1. It should be noted that in the present invention, only one antigen needs to be purified, which saves the tedious operation of purifying multiple antigens separately and performing ratio combination, and improves the preparation efficiency of immune antigens.
[0008] Another aspect of the present invention provides a nucleic acid molecule encoding the above-mentioned fusion antigen. It should be noted that the nucleic acid molecules that can encode the above-mentioned amino acid fusion antigen as shown in SEQ ID NO: 1 are all protected in the present invention, such as the nucleic acid molecule whose nucleotide sequence can be as shown in SEQ ID NO: 2; of course, it also includes the nucleic acid molecule optimized on the basis of the nucleotide sequence as shown in SEQ ID NO: 2, and the optimization can be performed according to methods known in the art.
[0009] In another aspect, the present invention provides a product for detecting Haemophilus parasuis or diagnosing Haemophilus parasuis infection diseases, which includes the above-mentioned Haemophilus parasuis fusion antigen. It should be noted that the above-mentioned product can be a reagent or a kit, that is, the above-mentioned fusion antigen can be prepared into a reagent or a kit for detecting Haemophilus parasuis or diagnosing Haemophilus parasuis infection diseases. In addition, Haemophilus parasuis infection diseases include all diseases infected with Haemophilus parasuis, such as porcine Gramsci disease.
[0010] In another aspect, the present invention provides a recombinant subunit vaccine for preventing and treating Haemophilus parasuis infection diseases, which comprises the above-mentioned Haemophilus parasuis fusion antigen or the above-mentioned nucleic acid molecule.
[0011] Another aspect of the present invention provides a use of the above Haemophilus parasuis fusion antigen or the above nucleic acid molecule in the preparation of a product for detecting Haemophilus parasuis or diagnosing Haemophilus parasuis infection. It should be noted that, as mentioned above, the product can be a reagent or a kit.
[0012] In another aspect, the present invention provides a use of the above-mentioned Haemophilus parasuis fusion antigen or the above-mentioned nucleic acid molecule in the preparation of a recombinant subunit vaccine for preventing and treating Haemophilus parasuis infection diseases.
[0013] Preferably, in the above application, Haemophilus parasuis may include type 1 G05 strain and / or type 5 G06 strain and / or type 10 G07 strain and / or type 13 G08 strain.
[0014] Preferably, the Haemophilus parasuis infection disease may be porcine Gramser's disease.
[0015] The beneficial effects of the present invention include at least:
[0016] (1) The reactivity of the Glaesserella parasuis fusion antigen provided by the present invention was identified by Western-Blot, and it was found that the fusion protein antigen could be recognized by serum positive for Glaesserella parasuis antibodies, that is, the fusion protein had good immunoreactivity.
[0017] (2) Immunizing guinea pigs with the Glaesserella parasuis fusion antigen provided by the present invention obtained a protective effect against attack by Haemophilus parasuis type 1 G05 strain, type 5 G06 strain, type 10 G07 strain and type 13 G08 strain, and the immune protection effect was better than that of the corresponding Haemophilus parasuis whole-cell antigen inactivated vaccine.
[0018] (3) The Glaesserella parasuis fusion antigen provided by the present invention is easy to produce highly targeted immune protective antibodies after immunizing animals, avoiding immune tolerance and immune stress caused by non-related antigens caused by immunization with whole bacterial antigens. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1The amplification and identification results of the HAPS0926 gene sequence, LppC (middle) gene sequence, and VacJ gene sequence of Haemophilus parasuis, wherein M: DL 2000 DNA Mark, 1: amplified HAPS0926 gene sequence, 2: amplified LppC (middle) gene sequence, 3: amplified VacJ gene sequence;
[0020] Figure 2 Overlapping PCR splicing of HAPS0926 gene and LppC (middle) gene sequence, where M: DL2000 DNA Mark, 1, 2: spliced HAPS0926 + LppC (middle) gene sequence;
[0021] Figure 3 Overlapping PCR splicing of HAPS0926+LppC(middle)+VacJ gene sequences, where M: DL2000 DNA Mark, 1, 2: spliced HAPS0926+LppC(middle)+VacJ gene sequences;
[0022] Figure 4 PCR identification of the constructed Pet28a-(HAPS0926+LppC(middle)+VacJ) plasmid and strain, where M: DL 2000 DNA Mark, 1: constructed Pet28a-(HAPS0926+LppC(middle)+VacJ) plasmid, 2, 3, 4: screening of BL21(DE3) strain containing Pet28a-(HAPS0926+LppC(middle)+VacJ) plasmid;
[0023] Figure 5 The SDS-PAGE was used to identify the expression and purification of HAPS0926+LppC(middle)+VacJ fusion protein, where M: protein marker, 1: purified Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein;
[0024] Figure 6 Western-blot was used to identify the immunoreactivity of the purified expressed Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein antigen, wherein M: pre-stained protein marker, 1: expressed and purified Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein antigen. DETAILED DESCRIPTION
[0025] The examples are provided to better illustrate the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.
[0026] The terms used herein are only used to describe specific embodiments and are not intended to limit the present disclosure. Unless the context has a significantly different meaning, expressions in the singular include expressions in the plural. As used herein, it should be understood that terms such as "include", "have", "include" are intended to indicate the presence of features, numbers, operations, components, parts, elements, materials or combinations. The terms of the present invention are disclosed in the specification, and are not intended to exclude the possibility that one or more other features, numbers, operations, components, parts, elements, materials or combinations thereof may exist or may be added. As used herein, " / " may be interpreted as "and" or "or", depending on the circumstances.
[0027] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with specific examples, but the content of the present invention is not limited to the following examples.
[0028] 1. Amplification of the gene sequence of Haemophilus parasuis HAPS0926 protein, the gene sequence of the middle region of LppC protein, and the gene sequence of VacJ protein
[0029] (I) Design of primers for amplification of Haemophilus parasuis HAPS0926 protein gene sequence, LppC protein middle region gene sequence, and VacJ protein gene sequence
[0030] According to the complete gene sequence of HPS-SH0165 strain registered in GenBank, with the sequence number of CP-001321, a pair of primers HAPS0926-F and HAPS0926-R were designed to amplify the gene sequence of HAPS0926, an immune protective antigen of Haemophilus parasuis, wherein the primer HAPS0926-F was added with a BamHⅠ restriction enzyme cleavage site (underlined) and protective bases (see Table 1 below); a pair of primers LppC(middle)-F and LppC(middle)-R were designed to amplify the gene sequence of the middle region of LppC protein, an immune protective antigen of Haemophilus parasuis (see Table 1 below); a pair of primers VacJ-F and VacJ-F were designed to amplify the gene sequence of VacJ-F, an immune protective antigen of Haemophilus parasuis. A pair of primers VacJ-F and VacJ-R, wherein primer VacJ-R is added with an XhoⅠ restriction enzyme cutting site (underlined) and protective bases (see Table 1 below); wherein primers HAPS0926-R and LppC (middle) -F are reverse complementary sequences, which are convenient for seamlessly splicing the Haemophilus parasuis HAPS0926 protein gene and the LppC protein middle region gene sequence by overlapping PCR. On the basis of obtaining the spliced sequence, the Haemophilus parasuis VacJ protein gene sequence is spliced to the end of the HAPS0926 + LppC (middle) fusion gene sequence by overlapping PCR using the reverse complement of primers LppC (middle) -R and VacJ-F.
[0031] Table 1 Primer pairs for amplification of Haemophilus parasuis HAPS0926 protein gene sequence, LppC protein middle region gene sequence, and VacJ protein gene sequence
[0032] name sequence HAPS0926-F 5'-cgggatccatgcgtaaattttattctcttg-3' (BamHI restriction site) HAPS0926-R 5'-acatcattttgattttcagcaaattgctcgccatatttag-3' LppC(middle)-F 5'-ctaaatatggcgagcaatttgctgaaaatcaaaatgatgt-3' LppC(middle)-R 5'-agaagtttaatttttttcatttctgcagaacgtgtgccaaa-3' VacJ-F 5'-tttggcacacgttctgcagaaatgaaaaaaattaaacttct-3' VacJ-R 5'-ggctcgagtcaatcaatattttttagctg-3' (XhoⅠ restriction site)
[0033] (II) Gene sequence amplification of Haemophilus parasuis HAPS0926
[0034] The HAPS0926 gene sequence was amplified by PCR using Haemophilus parasuis serotype 1 G05 strain as a template. After the amplification, the fragment was identified by using 1% agarose gel and the 777 bp specific target fragment of the HAPS0926 gene sequence was purified and recovered (see Figure 1 ), whose gene sequence is shown in SEQ ID NO:3; wherein, the PCR amplification conditions are shown in Table 2 below.
[0035] Table 2 Conditions for amplification of gene sequences of Haemophilus parasuis HAPS0926
[0036]
[0037] (III) Amplification of the LppC (middle) gene sequence of Haemophilus parasuis
[0038] The PCR amplification of the LppC (middle) gene sequence was performed using the Haemophilus parasuis serotype 1 G05 strain as a template. After the amplification, the agarose gel was used for identification and the 756 bp specific target fragment of the LppC (middle) gene sequence was purified and recovered (see Figure 1 ), whose gene sequence is shown in SEQ ID NO:4; wherein, the PCR amplification conditions are shown in Table 3 below.
[0039] Table 3 Amplification conditions of Haemophilus parasuis LppC (middle) gene sequence
[0040]
[0041] (III) Amplification of VacJ gene sequence of Haemophilus parasuis
[0042] The PCR amplification of the VacJ gene sequence was performed using the Haemophilus parasuis serotype 1 G05 strain as a template. After the amplification, the fragment was identified using a 1% agarose gel and the 747 bp specific target fragment of the VacJ gene sequence was purified and recovered (see Figure 1 ), whose gene sequence is shown in SEQ ID NO:5; wherein, the PCR amplification conditions are shown in Table 4 below.
[0043] Table 4 Conditions for amplification of the VacJ gene sequence of Haemophilus parasuis
[0044]
[0045] 2. Traceless splicing of Haemophilus parasuis HAPS0926+LppC(middle)+VacJ gene sequences
[0046] (I) Traceless splicing of Haemophilus parasuis HAPS0926+LppC (middle) gene sequences
[0047] The HAPS0926 gene sequence and LppC (middle) gene sequence amplified and purified above were seamlessly spliced by overlapping PCR. After the overlapping PCR was completed, the fragment was identified by a 1% agarose gel, and the gene sequence fragment of the seamless splicing of the HAPS0926 gene and LppC (middle) gene of Haemophilus parasuis was purified and recovered, with a size of 1533 bp (see Figure 2 ); Overlapping PCR specifically includes:
[0048] ①The first step PCR reaction:
[0049] HAPS0926 gene sequence and LppC (middle) gene sequence 2 μL each, 2× PrimeSTAR max DNA Polymerase 25 μL, ddH 2 O 21μL, total volume 50μL, then equally divided into two PCR tubes, 25μL system in each tube for the first step of PCR amplification; PCR reaction conditions: 95℃ denaturation for 5min before entering the cycle, cycle parameters are 94℃ 40s, 57℃ 30s, 72℃ 40s, after 5 cycles, 72℃ extension for 10min;
[0050] ②The second step PCR reaction:
[0051] After the amplification, the second step of PCR reaction was carried out. First, 50 μL of amplification system was prepared: 2 μL of 100 μmol / L HAPS0926-F primer, 2 μL of 100 μmol / L LppC (middle) -R primer, 25 μL of 2× PrimeSTAR max DNA Polymerase, ddH 2 O 21μL, and then divide 25μL of the system into two tubes where the first PCR reaction is completed, mix them evenly, and each tube now contains 50μL of the system for the second PCR amplification; the PCR reaction conditions are: denaturation at 95℃ for 5min before entering the cycle, the cycle parameters are 94℃ for 40s, 57℃ for 20s, and 72℃ for 50s, and after 20 cycles, extend at 72℃ for 10min.
[0052] (II) Traceless splicing of Haemophilus parasuis HAPS0926+LppC(middle)+VacJ gene sequences
[0053] The overlapping PCR method was used again to splice the above-mentioned HAPS0926+LppC (middle) gene fusion sequence with the VacJ gene sequence; after the overlapping PCR amplification was completed, it was identified using a 1% agarose gel, and the gene sequence fragment of Haemophilus parasuis HAPS0926+LppC (middle)+VacJ gene seamless splicing was purified and recovered, with a size of 2280 bp (see Figure 3 ).
[0054] ①The first step PCR reaction:
[0055] 2 μL of the spliced HAPS0926+LppC (middle) gene sequence and VacJ gene sequence, 25 μL of 2× PrimeSTARmax DNA Polymerase, ddH 2O 21μL, total volume 50μL, then equally divided into two PCR tubes, 25μL per tube for the first step of PCR amplification. PCR reaction conditions are: 95℃ denaturation for 5min, then enter the cycle, the cycle parameters are 94℃ 40s, 56℃ 40s, 72℃ 50s, after 5 cycles, 72℃ extension for 10min;
[0056] ① The second step PCR reaction:
[0057] After the amplification, the second step of PCR reaction was carried out. First, 50 μL of amplification system was prepared: 2 μL of 100 μmol / L HAPS0926-F primer, 2 μL of 100 μmol / L VacJ-R primer, 25 μL of 2× PrimeSTAR max DNA Polymerase, ddH 2 O 21μL, and then divide 25μL of the system into two tubes where the first PCR reaction is completed, mix them evenly, and each tube now contains 50μL of the system for the second PCR amplification; the PCR reaction conditions are: denaturation at 95℃ for 5min before entering the cycle, the cycle parameters are 94℃ for 40s, 58℃ for 30s, and 72℃ for 1min, and after 25 cycles, extend at 72℃ for 10min.
[0058] 3. Construction of expression vector of Haemophilus parasuis HAPS0926+LppC(middle)+VacJ gene fusion sequence
[0059] (1) The purified and recovered Haemophilus parasuis HAPS0926+LppC(middle)+VacJ gene fusion sequence was double-digested with BamHⅠ and XhoⅠ, and the plasmid vector Pet28a was double-digested with BamHⅠ and XhoⅠ;
[0060] (2) Then the HAPS0926+LppC (middle)+VacJ gene fusion sequence fragment was connected with the plasmid vector Pet28a at 4° C. for 16 hours; wherein the connection system is shown in Table 5 below;
[0061] Table 5 Connection system for connection with plasmid vector Pet28a
[0062] substance system HAPS0926+LppC(middle)+VacJ gene fusion sequence 4μL Pet28a 4μL 10× Ligation Buffer 1μL T4 DNA Ligase 1μL
[0063] (3) Then, the strain was transformed into BL21(DE3) competent cells by heat stress, spread on LB plates supplemented with kanamycin at a final concentration of 50 μg / mL, cultured at 37°C for 16 h, and single colonies were picked and inoculated into LB liquid medium containing 50 μg / mL kanamycin. The plasmid was extracted for identification;
[0064] (4) PCR screening to obtain the BL21 (DE3) strain containing the positive construction plasmid Pet28a-(HAPS0926+LppC (middle)+VacJ) (see Figure 4 ), the gene sequence of BL21(DE3) (HAPS0926+LppC(middle)+VacJ) is shown in SEQ ID NO:2.
[0065] IV. Expression, purification and reactogenicity identification of Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein
[0066] (I) Expression and purification of Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein
[0067] (1) After overnight culture of a single E. coli BL21 / pET28a-(HAPS0926+LppC(middle)+VacJ) colony, transfer the colony to a freshly prepared LB liquid medium containing kanamycin (50 μg / ml) at a 1% inoculum volume and culture at 37°C with shaking at 230 rpm for about 2.5 h. The OD 600nm to 0.8-1.0, add IPTG to a final concentration of 0.8mmol / L, transfer to 37°C, shake and culture at 240rpm for 7h, and collect the cells by centrifugation;
[0068] (2) Wash the cells three times with PBS buffer, collect the cells by centrifugation for the last time and wash with Lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH = 8.0) to suspend the cells;
[0069] (3) Add lysozyme to a final concentration of 1 mg / mL, place on ice for 30 min, sonicate the cells (400 W power, 5 s sonication time, 5 s interval, 30 min sonication), centrifuge at 10,000 rpm for 15 min at 4°C, and collect the supernatant;
[0070] (4) The supernatant of the centrifuged bacterial solution was filtered through a 0.45 μm filter, and 5 mL was added to an affinity chromatography column containing 50% Ni-NTA. The mixture was shaken at 200 r / min for 1 h and then passed through the column. After the liquid was drained, 5 mL of Wash buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 50 mM imidazole, pH = 8.0) for 2 times;
[0071] (5) Finally, add 0.5 mL of Elution buffer (50 mM NaH 2 PO 4 , 300mM NaCl, 300mM Mimidazole, pH=8.0) to elute and collect the target protein. The concentration of the purified protein was determined to be 1.8mg / mL, and SDS-PAGE electrophoresis was performed to identify the results. The results are as follows Figure 5 The specific protein band obtained was about 97KD, which was consistent with the expected size (see Figure 5 ), the sequence of which is shown in SEQ ID NO:1.
[0072] (II) Identification of the reactogenicity of Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein
[0073] After the SDS-PAGE electrophoresis, Western-Blot was performed to identify the reactivity of the fusion protein antigen, which specifically includes the following steps:
[0074] (1) Pre-cut PVDF membrane and filter paper of the same size as the gel strip and immerse them in electrotransfer buffer; remove the gel, balance it in transfer buffer, and then lay the membrane, gel and filter paper in order (filter paper - PVDF membrane - gel - filter paper); seal it tightly and place it in the electrotransfer tank, add electrotransfer solution, connect the cooling device, and transfer at 400mA constant current for 30min;
[0075] (2) After the transfer is completed, remove the PVDF membrane and wash it with PBST for 10 min × 3 times;
[0076] (3) Place the PVDF membrane in 5% skim milk and block it at 4°C overnight. Discard the blocking solution and wash the membrane with PBST for 10 min × 3 times.
[0077] (4) Add the primary antibody, i.e., Haemophilus parasuis antibody-positive pig serum diluted with PBS (1:50), shake steadily at room temperature for 1 h, discard the primary antibody, and wash the membrane with PBST for 10 min × 4 times;
[0078] (5) Add horseradish peroxidase-labeled goat anti-swine enzyme-labeled secondary antibody, dilute with PBS at a ratio of 1:5000, shake steadily at room temperature for 1 h, discard the secondary antibody, and wash the membrane with PBST for 10 min × 3 times;
[0079] (6) The PVDF membrane treated with the secondary antibody was placed in a color developing solution for color development. After the specific reaction band appeared, the reaction was terminated and photographed for preservation. The results of Western-blot analysis showed that the fusion protein antigen of Haemophilus parasuis HAPS0926+LppC(middle)+VacJ could be recognized by the serum positive for Haemophilus parasuis antibody, indicating that the obtained fusion protein antigen had good immunogenicity (see Figure 6 ).
[0080] 5. Animal Experiments
[0081] (I) Immunization of guinea pigs with Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein antigen and determination of antibodies
[0082] (1) A total of 72 clean-grade female guinea pigs (weight 1.5-2 kg / guinea pig) were purchased and randomly divided into 12 groups, with 6 guinea pigs in each group. Each guinea pig in Groups 1, 2, 3, and 4 was immunized with Haemophilus parasuis HAPS0926+LppC (middle)+VacJ fusion protein antigen; Groups 5, 6, 7, and 8 were immunized with whole-bacterium inactivated vaccines prepared from Haemophilus parasuis type 1 G05 strain, type 5 G06 strain, type 10 G07 strain, and type 13 G08 strain, respectively, as positive controls; Groups 9, 10, 11, and 12 were immunized with PBS+adjuvant, as negative controls.
[0083] (2) Immunization was performed by multiple subcutaneous injections at the back. In the first, second, third and fourth groups, the purified expressed Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein antigen was mixed with an equal amount of Freund's complete adjuvant and emulsified. Each guinea pig was inoculated with 0.5 mL of the fusion antigen, and the content of the inoculated fusion antigen was 18 μg / guinea pig. The positive control groups of the fifth, sixth, seventh and eighth groups were respectively immunized with the whole bacteria inactivated antigen of Haemophilus parasuis type 1 G05 strain, type 5 G06 strain, type 10 G07 strain and type 13 G08 strain and emulsified with Freund's complete adjuvant, and each guinea pig was immunized with 0.5 mL of the mixture of PBS and Freund's complete adjuvant emulsified. In the subsequent immunizations, the corresponding antigens were mixed with Freund's incomplete adjuvant and emulsified. The same immunization dose and method were used. Each immunization was separated by 15 days. On the 10th day after the second immunization, blood was collected to separate the serum for the determination of antibody titer.
[0084] (3) The ELISA plate (100 μL / well) was coated with the expressed and purified Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein antigen (1.0 μg / mL), incubated at 4°C overnight, washed three times with PBST, blocked with 0.01 g / mL BSA at 100 μL / well, incubated at 37°C for 2 h, washed three times with PBST, the collected guinea pig serum was diluted 1:100 with PBS, 100 μL / well, incubated at 37°C for 30 min, washed three times with PBST; HRP-labeled goat anti-guinea pig enzyme-labeled secondary antibody was diluted 1:20,000, 100 μL / well, incubated at 37°C for 30 min, washed three times with PBST; TMP single-component substrate was added at 100 μL / well, color developed at 37°C for 10 min, the reaction was terminated with 2 M sulfuric acid stop solution, 100 μL / well, and the OD was read using an ELISA reader. 450nm The results are shown in Table 6.
[0085] Table 6 Results of antibody detection of guinea pig HAPS0926+LppC(middle)+VacJ fusion protein in each experimental group
[0086]
[0087]
[0088] As shown in Table 6, the serum antibodies of guinea pigs immunized with Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein antigen were all positive, and the average OD 450nm The serum antibodies of guinea pigs immunized with the whole bacterial antigen vaccine of Haemophilus parasuis were also positive, with an average OD of 450nm was 1.156; however, the antibody level of the HAPS0926+LppC(middle)+VacJ fusion protein antigen immunization group was significantly higher than that of the whole bacterial antigen vaccine; the fusion protein antibodies of guinea pigs in the negative control group were all negative, and the average OD 450nm It is 0.216.
[0089] (II) The protective effect of guinea pigs immunized with HAPS0926+LppC(middle)+VacJ fusion protein antigen against different serotypes of Haemophilus parasuis
[0090] Guinea pigs immunized with the above-mentioned Haemophilus parasuis HAPS0926+LppC(middle)+VacJ fusion protein antigen, guinea pigs immunized with whole-bacterium inactivated antigens of different strains, and guinea pigs immunized with PBS were challenged by intraperitoneal injection using type 1 G05 strain, type 5 G06 strain, type 10 G07 strain, and type 13 G08 strain, respectively. The protective effect of the guinea pigs in each immunization group was observed. The results are shown in Table 7.
[0091] Table 7 The challenge protection survival rate of guinea pigs in each immunization group
[0092]
[0093] It can be seen from Table 7 above that the protection rate of guinea pigs in the group immunized with the HAPS0926+LppC(middle)+VacJ fusion protein antigen against type 1 G05 strain, type 5 G06 strain, type 10 G07 strain and type 13 G08 strain was 83.33%; the corresponding protection rate of guinea pigs immunized with the whole-bacterium inactivated antigen vaccine of Haemophilus parasuis against type 1 G05 strain, type 5 G06 strain, type 10 G07 strain and type 13 G08 strain was 66.67%; this indicates that the fusion protein antigen immunization group has corresponding immune protection against Haemophilus parasuis serotypes 1, 5, 10 and 13, and the survival rate of protection against infection is higher than that of the group immunized with the whole-bacterium antigen vaccine of Haemophilus parasuis.
[0094] In addition, the guinea pigs in the negative control immunization group showed obvious clinical symptoms after the virus attack, including accelerated breathing, depression, and rough fur, and all died during the observation period.
[0095] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.
Claims
1. Glaesserella parasuis fusion antigen, It is characterized in that Its amino acid sequence is shown in SEQ ID NO:
1.
2. A nucleic acid molecule, It is characterized in that It encodes the Haemophilus parasuis fusion antigen described in claim 1.
3. The nucleic acid molecule according to claim 2, wherein the nucleotide sequence is shown in SEQ ID NO:
2.
4. A reagent for detecting Haemophilus parasuis or diagnosing Haemophilus parasuis infection diseases, It is characterized in that The invention comprises the Haemophilus parasuis fusion antigen as described in claim 1; the Haemophilus parasuis comprises one or more of serotype 1 strain, serotype 5 strain, serotype 10 strain or serotype 13 strain.
5. The reagent according to claim 4, It is characterized in that Reagents include kits.
6. A recombinant subunit vaccine for preventing and treating Haemophilus parasuis infection. It is characterized in that It comprises the Haemophilus parasuis fusion antigen of claim 1 or the nucleic acid molecule of claim 2 or 3; the Haemophilus parasuis comprises one or more of serotype 1 strain, serotype 5 strain, serotype 10 strain or serotype 13 strain.
7. Use of the Haemophilus parasuis fusion antigen of claim 1 or the nucleic acid molecule of claim 2 or 3 in the preparation of a product for detecting Haemophilus parasuis or diagnosing a disease infected by Haemophilus parasuis; Haemophilus parasuis includes one or more of serotype 1 strains, serotype 5 strains, serotype 10 strains or serotype 13 strains.
8. Use of the Haemophilus parasuis fusion antigen of claim 1 or the nucleic acid molecule of claim 2 or 3 in the preparation of a recombinant subunit vaccine for preventing and treating Haemophilus parasuis infection; Haemophilus parasuis includes one or more of serotype 1 strains, serotype 5 strains, serotype 10 strains or serotype 13 strains.
9. The use according to claim 8, It is characterized in that The disease caused by infection with Haemophilus parasuis is Gramsciosis in pigs.
